Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

MHRA Will Rewrite UK Gene Therapy Definition After 83% of Consultation Respondents Back Change

The MHRA will amend UK law to define gene therapy medicines by mechanism after 83% of 48 consultation respondents backed the change.

Published 19 Nov 2026· 7 minute read
Scientists in a U.S. FDA laboratory on the NIH campus in Bethesda that works on cellular, tissue and gene therapies
Photo: The U.S. Food and Drug Administration / Wikimedia Commons, Public domain (cropped). Source

The Medicines and Healthcare products Regulatory Agency (MHRA) and Northern Ireland’s Department of Health have confirmed, in a government response published on GOV.UK on 19 November 2026, that they intend to amend UK law so that gene therapy medicinal products are defined by how they work rather than by biological origin. The change matters to developers of gene-editing and synthetic nucleic acid medicines, including university groups and the research offices that sponsor their trials.

What the MHRA and the Department of Health announced

The government response closes a six-week consultation that ran from 11 May to 22 June 2026, which the MHRA ran jointly with the Department of Health in Northern Ireland. The two bodies conclude that there is “a clear case” for updating Regulation 2A of the Human Medicines Regulations 2012 and say they intend to proceed with secondary legislation in line with the policy approach set out in the response’s Appendix 1. The response also says the MHRA will consider developing guidance as the changes are implemented. The consultation outcome page on GOV.UK records the response as published on 19 November 2026; the document’s cover is dated 17 November.

The consultation drew 48 responses: 12 from individuals (25%) and 36 from organisations (75%). Overall, 83% of respondents (40 of 48) supported the proposed changes and 10% (5 of 48) disagreed or strongly disagreed. Of the 36 organisations, 8 were biotech or pharmaceutical developers, 6 were health and care providers such as NHS organisations, 5 were charities, 5 were professional bodies and 2 were universities or academic institutions.

Key details of the new definition

Appendix 1 of the response sets out the redrafted Regulation 2A. Under it, a medicinal product would be a gene therapy medicinal product if it has either of two sets of characteristics:

  • Genome editing: it contains or consists of substances that edit a target genome in a sequence-specific manner, or of cells whose genome has been edited in a sequence-specific manner.
  • Recombinant or synthetic nucleic acids: it contains or consists of a recombinant or synthetic nucleic acid intended to regulate, replace or add a nucleic acid sequence and which mediates its effect by being transcribed or translated, or it consists of cells subjected to such a nucleic acid.

The draft text also states that a vaccine against infectious diseases is not to be treated as a gene therapy medicinal product. The response lists the main decisions behind that drafting:

Question Respondent view MHRA and Department of Health position
Products made from non-biological starting material can be gene therapy medicinal products 98% (47 of 48) agreed Proceed; classification does not imply identical regulatory requirements
Synthetic or recombinant nucleic acids count only where they are transcribed or translated 75% (36 of 48) agreed; 15% (7 of 48) disagreed Proceed; antisense oligonucleotides and siRNAs are not reclassified
Deliberate, sequence-specific genome editing counts regardless of the active substance 96% (46 of 48) agreed Proceed; no separate category for non-genome-modifying nucleic acid medicines
Epigenetic or epitranscriptomic modulation alone counts 40% (19 of 48) supported; 43% (21 of 48) did not agree Not included; the MHRA will monitor the field and may issue guidance
Genetic material need not itself produce the therapeutic effect 66% (32 of 48) supported; 13% (6 of 48) disagreed Proceed; the product must still meet the statutory definition of a medicinal product
A “long-lasting” expression criterion, as proposed in the EU 21% (10 of 48) supported; 65% (31 of 48) did not Not adopted; the UK keeps a technology-focused definition

On where the activity happens, 85% of respondents (41 of 48) backed keeping the existing approach, under which the mechanism rather than the cell type decides classification. A product can qualify whether the activity occurs in patient cells, donor cells, engineered bacteria or other cells, and whether delivery uses viral vectors, bacteriophages or other vectors. A recombinant or synthetic nucleic acid includes any sequence not directly found in nature.

Background: why the 2007 definition no longer fits

The current definition dates from 2007 and was retained in the Human Medicines Regulations 2012. The response explains that, as it stands, a gene therapy medicinal product must be a biological medicinal product containing a recombinant nucleic acid, with a therapeutic, prophylactic or diagnostic effect that relates directly to that sequence or to the product of its expression. Synthetic nucleic acids, genome-editing approaches that do not rely on recombinant nucleic acids, and engineered cells carrying genetic modifications for safety or control functions, such as safety switches, do not fit neatly.

When the MHRA opened the consultation on 11 May, its announcement quoted Jon Beaman, MHRA Deputy Director for Innovative Medicines, saying the teams had designed the updates “to ensure that patient safety remains at the centre of any change”. The agency said the amendments would not alter the approval pathway, the regulatory status of licensed products or the existing safety, quality and efficacy standards. Manufacturing Chemist and AABB reported the same proposals at the time.

Reaction: what respondents told the regulator

The response summarises respondents’ free-text comments alongside the votes. Respondents said synthetic nucleic acid products may be functionally equivalent to biologically derived ones, but that classification parity is not risk parity, because manufacturing processes, impurity profiles and quality attributes can differ. On the nucleic acid boundary, about a quarter of individual respondents from academia and industry (3 of 12) argued for bringing antisense oligonucleotides and siRNAs inside the framework; the MHRA and the Department of Health replied that doing so could bring new manufacturing standards, pharmacovigilance obligations and other requirements to established, marketed medicines.

On the “long-lasting” criterion, respondents said the term lacks a clear scientific definition, is hard to apply consistently and could create uncertainty about authorised products. The response says the UK definition departs from emerging EU terminology by deliberate policy choice, to improve scientific clarity and avoid excluding clinically relevant technologies. In a May analysis, the law firm Arnold & Porter warned that “classification divergence risks are likely to remain” for synthetic nucleic acids, non-viral delivery and novel editing mechanisms.

What it means for researchers, universities and research offices

Classification as a gene therapy medicinal product places a product in the advanced therapy framework, and the response notes that the change is intended to give developers greater certainty and to keep the UK attractive for clinical trials, research and manufacture. The response stresses that classification “does not imply identical regulatory requirements” and that expectations remain risk-based and proportionate to each product.

  • Gene-editing programmes: products whose mechanism involves deliberate, sequence-specific editing fall inside the definition whatever the active substance. Academic groups developing editing reagents or edited cells for clinical use should plan on that basis; our comparison of cell therapy and gene therapy explains how the two modalities differ operationally.
  • Synthetic constructs and engineered cells: synthetic nucleic acids that are transcribed or translated would fall inside the definition, as would cells whose genetic modification serves a safety or control function rather than directly delivering the therapeutic effect. The Arnold & Porter analysis noted that developers of synthetic products may need to reassess their classification.
  • Established nucleic acid medicines: antisense oligonucleotides and siRNAs stay outside the advanced therapy framework, so existing programmes on those platforms are not reclassified.
  • Personalised mRNA cancer therapies: the infectious-disease vaccine exclusion does not extend to individualised mRNA cancer immunotherapies that otherwise meet the criteria.
  • Trial sponsors: sponsors working through the UK’s evolving trial rules should read the definition alongside the 2026 UK clinical trials regulations reform and their CTIMP classification decisions. For a non-UK comparison, see our guide to the FDA approval pathway for gene therapy.

What happens next

The MHRA and the Department of Health intend to proceed with secondary legislation to implement the revised definitions in line with Appendix 1, and the MHRA will consider developing guidance to support stakeholders as the proposals are implemented. The response says the MHRA will continue to monitor epigenetic and epitranscriptomic technologies and may provide additional product classification guidance as they mature. Respondents noted that the costs of assessing the changes are likely to be transitional, and that patient access also depends on other parts of the healthcare system once a therapy is licensed.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →